Cargando…
Autologous HER2 CMV bispecific CAR T cells are safe and demonstrate clinical benefit for glioblastoma in a Phase I trial.
Autores principales: | Ahmed, Nabil, Brawley, Vita, Hegde, Meenakshi, Bielamowicz, Kevin, Wakefield, Amanda, Ghazi, Alexia, Ashoori, Aidin, Diouf, Oumar, Gerken, Claudia, Landi, Daniel, Kalra, Mamta, Yi, Zhongzhen, Rooney, Cliona, Dotti, Gianpietro, Gee, Adrian, Heslop, Helen, Gottschalk, Stephen, Powell, Suzanne, Grossman, Robert, Wels, Winfried, Kew, Yzonne, Baskin, David, Zhang, Jonathan, New, Pamela, Hicks, John |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4645467/ http://dx.doi.org/10.1186/2051-1426-3-S2-O11 |
Ejemplares similares
-
TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy
por: Grada, Zakaria, et al.
Publicado: (2013) -
A bispecific chimeric antigen receptor molecule enhances T cell activation through dual immunological synapse formation and offsets antigen escape in glioblastoma
por: Hegde, Meenakshi, et al.
Publicado: (2015) -
Is CMV a target in pediatric glioblastoma? Expression of CMV proteins, pp65 and IE1-72 and CMV nucleic acids in a cohort of pediatric glioblastoma patients
por: Wakefield, Amanda, et al.
Publicado: (2015) -
Combinational Targeting Offsets Antigen Escape and Enhances Effector Functions of Adoptively Transferred T Cells in Glioblastoma
por: Hegde, Meenakshi, et al.
Publicado: (2013) -
Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety
por: Hoyos, Valentina, et al.
Publicado: (2010)